This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
by Zacks Equity Research
Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.
Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study
by Zacks Equity Research
Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.
AlloVir (ALVR) Begins Study to Prevent Six Viral Infections
by Zacks Equity Research
AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.
Zacks.com featured highlights include Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals
by Zacks Equity Research
Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals are part of today's Screen of the Week blog.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks including CRI, TH, IQ, BKE and CRBP with increasing P/E ratios.
Is it the Right Time to Add Mednax (MD) Stock to Your Kitty?
by Zacks Equity Research
Growing revenues, numerous acquisitions, diversified care network and adequate cash generation abilities are likely to continue driving Mednax (MD).
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -2.70% and 12.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Onto Acadia Healthcare (ACHC) Now
by Zacks Equity Research
Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.
After Plunging 29.4% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Corbus Pharmaceuticals (CRBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Jazz Pharma (JAZZ) Begins Zepzelca Confirmatory Study for SCLC
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) and partner PharmaMar initiate a late-stage study to evaluate Zepzelca in metastatic SCLC. Data from the study will support full approval of the drug for the indication.
Down 31.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corbus Pharmaceuticals (CRBP)
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cannabis ETF Tops in January: 5 Stocks That Led the Way
by Sweta Killa
Inside the top performing stocks in the top ETF of January.
Corbus Pharmaceuticals (CRBP) Catches Eye: Stock Jumps 7.3%
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -4.88% and -64.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis (ACB) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) fiscal first-quarter results are likely to reflect solid prospects in the Canadian market.